Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B

Basit Öğe Kaydı
dc.contributor.authorKolgelier, Servet
dc.contributor.authorDemir, Nazlim Aktug
dc.contributor.authorInkaya, Ahmet Cagkan
dc.contributor.authorSumer, Sua
dc.contributor.authorOzcimen, Serap
dc.contributor.authorDemir, Lutfi Saltuk
dc.contributor.authorPehlivan, Fatma Seher
dc.date.accessioned2020-03-26T19:07:03Z
dc.date.available2020-03-26T19:07:03Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Hepatologists have studied serologic markers of liver injury for decades. Annexins are a prominent group of such markers and annexin A2 (AnxA2) is one of the best characterized annexins. AnxA2 inhibits HBV polymerase among other functions. Its expression is up-regulated in regenerative hepatocytes. Objectives: To determine if serum AnxA2 level has a role in estimating liver damage in chronic HBV infection and investigate whether AnxA2 levels correlate with hepatic fibrosis. Patients and Methods: This study included 173 patients with chronic hepatitis B (CHB) and 51 healthy controls. Liver fibrosis was graded histologically on liver biopsy samples. Blood samples were taken from patients during biopsy and serum AnxA2 levels were measured with ELISA. Results: In a group of adult patients with CHB, AnxA2 values were far higher than those of the control group (P = 0.001). When we assessed AnxA2 levels based on fibrosis stages, serum AnxA2 levels of patients with early stage fibrosis (stages 1 - 3) were significantly higher than those of patients with advanced stage fibrosis (stages 4 - 5; P = 0.001). Conclusions: AnxA2 is a useful biomarker for early stage fibrosis in patients with CHB.en_US
dc.identifier.doi10.5812/hepatmon.30655en_US
dc.identifier.issn1735-143Xen_US
dc.identifier.issn1735-3408en_US
dc.identifier.issue10en_US
dc.identifier.pmid26587036en_US
dc.identifier.urihttps://dx.doi.org/10.5812/hepatmon.30655
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32542
dc.identifier.volume15en_US
dc.identifier.wosWOS:000368272800005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKOWSAR PUBLen_US
dc.relation.ispartofHEPATITIS MONTHLYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnnexin A2en_US
dc.subjectHepatitis Ben_US
dc.subjectChronicen_US
dc.subjectLiver Fibrosisen_US
dc.subjectBiological Markeren_US
dc.titleSerum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu